UA117506C2 - Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти - Google Patents

Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти

Info

Publication number
UA117506C2
UA117506C2 UAA201607988A UAA201607988A UA117506C2 UA 117506 C2 UA117506 C2 UA 117506C2 UA A201607988 A UAA201607988 A UA A201607988A UA A201607988 A UAA201607988 A UA A201607988A UA 117506 C2 UA117506 C2 UA 117506C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical preparation
acetic acid
intraocular pressure
lowering
acid compound
Prior art date
Application number
UAA201607988A
Other languages
English (en)
Ukrainian (uk)
Inventor
Нейвід Шамс
Хенк-Андре Крун
Хісасі Кавата
Норіко Кавабата
Original Assignee
Сантен Фармас'Ютікал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117506(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сантен Фармас'Ютікал Ко., Лтд. filed Critical Сантен Фармас'Ютікал Ко., Лтд.
Publication of UA117506C2 publication Critical patent/UA117506C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201607988A 2014-01-10 2015-01-08 Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти UA117506C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925882P 2014-01-10 2014-01-10
PCT/JP2015/050366 WO2015105144A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物を含む医薬製剤

Publications (1)

Publication Number Publication Date
UA117506C2 true UA117506C2 (uk) 2018-08-10

Family

ID=53520400

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201607988A UA117506C2 (uk) 2014-01-10 2015-01-08 Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти

Country Status (26)

Country Link
US (9) US9415038B2 (enExample)
EP (3) EP3424503B1 (enExample)
JP (7) JP5846338B2 (enExample)
KR (1) KR101824829B1 (enExample)
CN (2) CN108743587B (enExample)
AU (1) AU2015205188B2 (enExample)
BR (1) BR112016015763B8 (enExample)
CA (1) CA2936026C (enExample)
CL (1) CL2016001756A1 (enExample)
DK (1) DK3093018T3 (enExample)
EA (1) EA031734B1 (enExample)
ES (2) ES2711091T3 (enExample)
GE (1) GEP20186917B (enExample)
HK (1) HK1223036A1 (enExample)
HU (1) HUE041653T2 (enExample)
IL (1) IL246447B (enExample)
MX (1) MX370361B (enExample)
MY (1) MY163235A (enExample)
PH (1) PH12016501357B1 (enExample)
PL (1) PL3093018T3 (enExample)
PT (1) PT3093018T (enExample)
SG (1) SG11201605653RA (enExample)
TR (1) TR201902019T4 (enExample)
TW (1) TWI598113B (enExample)
UA (1) UA117506C2 (enExample)
WO (1) WO2015105144A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3888654B1 (en) * 2014-01-10 2023-06-14 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil containing pharmaceutical composition
EP3424503B1 (en) 2014-01-10 2020-09-02 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
MX2016009049A (es) * 2014-01-10 2016-09-09 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
MX2017007572A (es) * 2014-12-12 2018-02-09 Kowa Co Composicion acuosa.
HK1249443A1 (en) * 2015-07-01 2018-11-02 Santen Pharmaceutical Co., Ltd Depot preparation containing citric acid ester
JP7032134B2 (ja) * 2015-07-09 2022-03-08 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤
JPWO2018230713A1 (ja) 2017-06-16 2020-04-16 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
WO2018230711A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 ｍＴＯＲインヒビターを含む、眼の症状、障害または疾患を治療または予防するための医薬およびその応用
TWI842679B (zh) * 2017-09-29 2024-05-21 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥
JPWO2019124487A1 (ja) * 2017-12-21 2020-12-10 参天製薬株式会社 オミデネパグの組合せ
TWI842692B (zh) * 2017-12-28 2024-05-21 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥製劑
SI3681500T1 (sl) * 2018-04-24 2022-09-30 Allergan, Inc. Uporaba pilokarpinijevega hidroklorida za zdravljenje presbiopije

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
LT2264009T (lt) 2008-03-12 2019-04-25 Ube Industries, Ltd. Piridilaminoacto rūgšties junginys
PL2415763T3 (pl) * 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
EP3888654B1 (en) 2014-01-10 2023-06-14 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil containing pharmaceutical composition
EP3424503B1 (en) 2014-01-10 2020-09-02 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
MX2016009049A (es) * 2014-01-10 2016-09-09 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.

Also Published As

Publication number Publication date
JPWO2015105144A1 (ja) 2017-03-23
US20250235439A1 (en) 2025-07-24
CA2936026C (en) 2022-04-19
ES2711091T3 (es) 2019-04-30
WO2015105144A1 (ja) 2015-07-16
BR112016015763B8 (pt) 2020-09-15
CN108743587B (zh) 2021-04-30
EP3424503B1 (en) 2020-09-02
BR112016015763B1 (pt) 2020-09-01
TWI598113B (zh) 2017-09-11
EP3750541A1 (en) 2020-12-16
EA201691402A1 (ru) 2016-10-31
JP2022111280A (ja) 2022-07-29
CN108743587A (zh) 2018-11-06
KR20160101030A (ko) 2016-08-24
MX370361B (es) 2019-12-10
JP6491588B2 (ja) 2019-03-27
PH12016501357A1 (en) 2016-08-15
EP3093018B1 (en) 2018-11-28
US20180169079A1 (en) 2018-06-21
EP3093018A4 (en) 2017-09-13
AU2015205188A1 (en) 2016-07-14
CA2936026A1 (en) 2015-07-16
PH12016501357B1 (en) 2020-12-09
SG11201605653RA (en) 2016-08-30
EA031734B1 (ru) 2019-02-28
TW201609186A (zh) 2016-03-16
CN105899209A (zh) 2016-08-24
CL2016001756A1 (es) 2017-05-12
JP2024019479A (ja) 2024-02-09
TR201902019T4 (tr) 2019-03-21
US10702511B2 (en) 2020-07-07
US20220054466A1 (en) 2022-02-24
US11793798B2 (en) 2023-10-24
JP6785330B2 (ja) 2020-11-18
JP2021006593A (ja) 2021-01-21
US20200289483A1 (en) 2020-09-17
US9943510B2 (en) 2018-04-17
JP7402922B2 (ja) 2023-12-21
US11197849B2 (en) 2021-12-14
JP5846338B2 (ja) 2016-01-20
GEP20186917B (en) 2018-11-12
JP2016027060A (ja) 2016-02-18
US20150196541A1 (en) 2015-07-16
KR101824829B1 (ko) 2018-02-01
JP2019108363A (ja) 2019-07-04
MY163235A (en) 2017-08-30
AU2015205188B2 (en) 2019-11-14
CN105899209B (zh) 2018-09-11
JP7087040B2 (ja) 2022-06-20
US12295946B2 (en) 2025-05-13
PT3093018T (pt) 2019-01-10
NZ721620A (en) 2021-08-27
EP3424503A1 (en) 2019-01-09
MX2016009063A (es) 2016-09-28
HK1223036A1 (zh) 2017-07-21
US20240000763A1 (en) 2024-01-04
EP3093018A1 (en) 2016-11-16
US20190105310A1 (en) 2019-04-11
IL246447A0 (en) 2016-08-31
DK3093018T3 (en) 2019-02-04
USRE48183E1 (en) 2020-09-01
HUE041653T2 (hu) 2019-05-28
US20160324838A1 (en) 2016-11-10
IL246447B (en) 2020-06-30
US10179127B2 (en) 2019-01-15
US9415038B2 (en) 2016-08-16
PL3093018T3 (pl) 2019-05-31
JP2025142352A (ja) 2025-09-30
ES2834334T3 (es) 2021-06-17
JP7726542B2 (ja) 2025-08-20

Similar Documents

Publication Publication Date Title
UA117506C2 (uk) Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
NZ739211A (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
JP2016027060A5 (enExample)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
EP4494705A3 (en) Non-peptide oxytocin receptor agonists
EP4338751A3 (en) Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
WO2017168454A3 (en) Novel compounds as btk inhibitors
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure